PHARMAECONOMICA conducts state-of-the-art literature reviews and meta-analyses using the most rigorous methodologies, to ensure the reliability and reproducibility of the answers to your research questions.

High-quality literature reviews allow for an understanding of:

• Disease patterns including etiology, definitions, and diagnosis

• Epidemiologic, humanistic, and economic burden of the disease

• Clinical Guidelines and patterns in clinical practice

• Data and performance of the comparator treatments

• Previous modeling exercises in the disease area

• Inputs of the economic models on identification, measurement, and valuation of resource usage and utility estimates

We perform high-quality meta-analyses:

• Pairwise meta-analysis (PMA): If the data from multiple trials are sufficiently homogenous, a pairwise meta-analysis can be performed to calculate pooled effect estimates. It involves groups of trials that compare the same two interventions directly (head-to-head)

• Network meta-analysis (NMA): NMA combines trials with different treatments and comparators into a single framework and it permits to simultaneously accommodate direct and indirect comparisons. It also allows the estimation of the ranking and hierarchy of interventions.

• Model-based meta-analysis (MBMA): MBMA  incorporates parametric pharmacology models (e.g., with dose and duration) and is able to integrate relevant pre-clinical, bio-marker, clinical safety, and efficacy data of competing treatment options in a certain disease area.

• Product’s clinical differentiation

• Prediction on how a new drug’s safety and efficacy profile might compare to the current SOC and other competitor drugs

• Treatment comparisons even if no head-to-head trial available

• Multi-treatment comparisons

• Inform cost-effectiveness models (populate cost-effectiveness models)

• Provide a ranking of the compared interventions for a particular outcome

• Understanding of a drug’s dose-response relationship

• Increase the probability of clinical trial success

• MBMA has emerged as a methodology that quantifies clinical trial efficacy, tolerability, and safety information to enable strategic drug development decisions. It provides a quantitative framework for differentiation by allowing one to understand how a new compound will perform relative to existing relevant comparators and /or drugs in development

To estimate both costs and consequences of alternative courses of action, models synthesize information on a range of variables such as natural history, clinical efficacy, health-related quality of life, resource use, and costs and results of these analytical models are used to decide which interventions represent good value for money from the perspective of a particular decision maker.

We can help if  your Organization requires  a model to:

• Understand disease patterns and unmet needs

• Support strategic planning

• Develop an economic evaluation

• Demonstrate value to inform payer decisions

Our experts use state-of-the-art methods to develop high-quality decision analytic models:

• Decision trees

• Markov and other stochastic process models

• Simulations (individual patient, discrete event, etc.)

• Infectious disease models

• Statistical analyses (survival analysis, multivariate regression, utility data analysis, etc.)

• Probabilistic, bivariate, univariate, and structural sensitivity analysis

• The expected value of perfect information

• Multi-criteria decision analysis

• Time-driven activity-based costing

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

• Our high-quality cost-effectiveness models can be used for submission purposes to demonstrate value for money and gain national reimbursement recommendations in the UK, North America, Australia, Canada, Sweden, The Netherlands …..

• A cost-effectiveness model also generates and demonstrates the economic value messages that will form a key component of the product value story to ensure the product’s market access and adoption.

• We can develop a full range of economic models to estimate the cost of disease, incremental cost-effectiveness ratio, value-based pricing, budget impact, and expected value of perfect information.

• Our experience covers spans across different therapeutic areas such as Cardiology, Oncology, Parenteral Nutrition, Epilepsy, Alzheimer, Infectious diseases (COVID, Ebola, Meningitis), etc.